Text size :

Jessica Scarpa case, Berardi (Aiom): “Treatments should not depend on the patient’s postal code”

ADNKRONOS

November 13, 2026

Rome, Nov 13. (Adnkronos Health) – The story of Jessica Scarpa “raises an issue that goes far beyond the single drug: we must change the way we measure innovation in oncology. It is not enough to develop increasingly effective therapies; we must also measure how long it takes for them to reach the patients who need them. Because, especially in the most aggressive tumors, time is an essential component of treatment possibilities.” So Rossana Berardi, president-elect of the Italian Association of Medical Oncology, told Adnkronos Health, on the sidelines of the XXVIII Aiom national congress underway in Rome, commenting on the appeal of Jessica Scarpa, a 36-year-old woman who has been suffering from metastatic pancreatic cancer for 2 years and who addresses anyone who listens to her in a new video published on the Change.org Italia channels: ‘daraxonrasib for all patients, sign the petition’. For her, Lombardy decided to purchase the drug in the United States.

“I believe the time has come to foresee a national early access pathway for oncological drugs that demonstrate significant clinical benefits – explains Berardi – with homogeneous eligibility criteria, defined times for evaluating requests, and agreements with pharmaceutical companies that allow their availability, using existing regulatory instruments. A system that allows early access to be accompanied by the collection of clinical data in real practice, so as to combine timeliness, safety, and sustainability.” Berardi also proposes “to introduce a national indicator for the time to access oncological innovation, which measures not only the authorization times, but above all the time elapsed between the identification of a therapeutic opportunity, the clinical request, and its effective availability for the patient. These data should be monitored and made public, also at a regional level, to identify and promptly correct inequalities. Because equity cannot remain a declared principle: it must become a concrete, measurable, and verifiable result.”

“We are not asking to give up the rigor of scientific evaluations, but to eliminate dead times and inequalities that can separate research progress from its clinical application. A patient – emphasizes Berardi, who is also a full professor of Oncology at the Polytechnic University of Marche and director of the Oncology Clinic of the Marche University Hospital – should not need a petition, a fundraiser, or media attention to access a therapeutic opportunity. The challenge of the future will be to guarantee everyone the timely right to care because a therapy that arrives too late risks becoming a missed opportunity.” The decision of the Lombardy Region “to intervene to allow Jessica Scarpa to access a new therapeutic opportunity is an important signal. But this matter must push us to a broader reflection: we cannot allow the right to a treatment opportunity to depend on the patient’s postal code or on the sensitivity and intervention capacity of the individual Region,” she concludes.

Jiji Press

Related

Page TOP